HOB Biotech Group Corp.,Ltd (SHA:688656)
China · Delayed Price · Currency is CNY 118.57
-3.38 (-2.77%)
Sep 11, 2026, 3:00 PM CST
SHA:688656 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 395.15 | 389.19 | 391.86 | 382.83 | 311 | 309.16 |
Other Revenue | 9.35 | 9.21 | 10.48 | 11.57 | 9.39 | 8.55 |
| 404.51 | 398.4 | 402.34 | 394.41 | 320.39 | 317.71 | |
Revenue Growth | 3.94% | -0.98% | 2.01% | 23.10% | 0.84% | 43.20% |
Cost of Revenue | 165.84 | 165.62 | 145.16 | 149.41 | 118.14 | 98.55 |
Gross Profit | 238.66 | 232.78 | 257.18 | 244.99 | 202.26 | 219.16 |
Selling, General & Admin | 161.91 | 159.97 | 160.69 | 140.05 | 118.76 | 99.87 |
Research & Development | 45.45 | 47.12 | 45.47 | 46.32 | 38.11 | 31.23 |
Other Operating Expenses | 8.89 | 7.59 | 6.47 | 4.83 | 3.64 | 3.32 |
Operating Expenses | 216.41 | 215.11 | 213.02 | 191.7 | 160.25 | 134.83 |
Operating Income | 22.26 | 17.67 | 44.16 | 53.3 | 42.01 | 84.33 |
Interest Expense | -0.93 | -2.15 | -2.71 | -2.53 | -1.92 | -1.24 |
Interest & Investment Income | 0.27 | 0.57 | 0.89 | 3.4 | 6.95 | 13.08 |
Currency Exchange Gain (Loss) | -0.81 | 0.61 | -0.53 | -0.01 | -0.15 | -0.46 |
Other Non Operating Income (Expenses) | -0.9 | -0.24 | -0.36 | -0.27 | -0.18 | 0 |
EBT Excluding Unusual Items | 19.89 | 16.46 | 41.46 | 53.89 | 46.71 | 95.72 |
Gain (Loss) on Sale of Investments | - | - | - | 0.43 | 0.22 | 0.01 |
Gain (Loss) on Sale of Assets | 5.12 | 4.7 | -0.75 | 0.03 | -0.47 | -0.08 |
Asset Writedown | - | - | -1.1 | - | - | - |
Other Unusual Items | 4.81 | 3.67 | 1.43 | 2.28 | 0.02 | 3.48 |
Pretax Income | 29.82 | 24.82 | 41.03 | 56.63 | 46.48 | 99.13 |
Income Tax Expense | 2.12 | 1.62 | 4.23 | 9.29 | 4.83 | 12.93 |
Net Income | 27.71 | 23.2 | 36.8 | 47.33 | 41.65 | 86.19 |
Net Income to Common | 27.71 | 23.2 | 36.8 | 47.33 | 41.65 | 86.19 |
Net Income Growth | -4.42% | -36.96% | -22.24% | 13.64% | -51.68% | 52.24% |
Shares Outstanding (Basic) | 62 | 63 | 62 | 63 | 63 | 62 |
Shares Outstanding (Diluted) | 62 | 63 | 63 | 64 | 63 | 62 |
Shares Change | -4.19% | -1.18% | -0.79% | 1.35% | 2.50% | 30.49% |
EPS (Basic) | 0.45 | 0.37 | 0.59 | 0.75 | 0.66 | 1.40 |
EPS (Diluted) | 0.45 | 0.37 | 0.58 | 0.74 | 0.66 | 1.40 |
EPS Growth | -0.24% | -36.21% | -21.62% | 12.12% | -52.86% | 16.67% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 55.38 | -0.96 | -54.15 | -75.34 | -161.9 | -63.09 |
Free Cash Flow Per Share | 0.90 | -0.01 | -0.85 | -1.18 | -2.56 | -1.02 |
Dividend Per Share | 0.200 | 0.200 | 0.300 | 0.400 | 0.300 | 0.530 |
Dividend Growth | -33.33% | -33.33% | -25.00% | 33.33% | -43.40% | 76.67% |
Gross Margin | 59.00% | 58.43% | 63.92% | 62.12% | 63.13% | 68.98% |
Operating Margin | 5.50% | 4.44% | 10.98% | 13.51% | 13.11% | 26.54% |
Profit Margin | 6.85% | 5.82% | 9.15% | 12.00% | 13.00% | 27.13% |
Free Cash Flow Margin | 13.69% | -0.24% | -13.46% | -19.10% | -50.53% | -19.86% |
EBITDA | 83.72 | 80.36 | 83.95 | 86.41 | 68.95 | 104.06 |
EBITDA Margin | 20.70% | 20.17% | 20.87% | 21.91% | 21.52% | 32.76% |
D&A For EBITDA | 61.46 | 62.69 | 39.78 | 33.12 | 26.94 | 19.73 |
EBIT | 22.26 | 17.67 | 44.16 | 53.3 | 42.01 | 84.33 |
EBIT Margin | 5.50% | 4.44% | 10.98% | 13.51% | 13.11% | 26.54% |
Effective Tax Rate | 7.09% | 6.53% | 10.31% | 16.41% | 10.39% | 13.05% |
Revenue as Reported | 404.51 | 398.4 | 402.34 | 394.41 | 320.39 | 317.71 |
Advertising Expenses | - | 10.58 | 10.05 | 9.61 | 8.73 | 6.51 |